Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy
Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 545
Referral date 01 October 2013
Topic area
  • Cancer
  • Gynaecology, pregnancy and birth

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager:

TBC

Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
14 April 2014 As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy .
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for pazopanib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual